Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. EZZ Life Science Holdings's annualized net income for the quarter that ended in Dec. 2025 was A$-1.28 Mil. EZZ Life Science Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$27.92 Mil. Therefore, EZZ Life Science Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -4.59%.
The historical rank and industry rank for EZZ Life Science Holdings's Return-on-Tangible-Equity or its related term are showing as below:
ASX:EZZ'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.86 Med: 27.27 Max: 38.83
Current: 10.86
During the past 6 years, EZZ Life Science Holdings's highest Return-on-Tangible-Equity was 38.83%. The lowest was 10.86%. And the median was 27.27%.
ASX:EZZ's Return-on-Tangible-Equity is ranked better than 87.57% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs ASX:EZZ: 10.86
EZZ Life Science Holdings (ASX:EZZ) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
EZZ Life Science Holdings Return-on-Tangible-Equity Related Terms
EZZ Life Science Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for EZZ Life Science Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings Return-on-Tangible-Equity Chart
ASX:EZZ vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -4.59% mean?
EZZ Life Science Holdings (ASX:EZZ) has a Return-on-Tangible-Equity of -4.59% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on EZZ Life Science Holdings and its competitors. Over the past decade, EZZ Life Science Holdings' Return-on-Tangible-Equity has ranged from 10.86 to 38.83. According to the industry distribution chart, EZZ Life Science Holdings ranks #149 out of 1199 companies in the Biotechnology industry, placing it in the top 12.4%.
Is EZZ Life Science Holdings' Return-on-Tangible-Equity too high?
EZZ Life Science Holdings' current Return-on-Tangible-Equity is -4.59%. Over the past 10 years, this metric has ranged from a low of 10.86 to a high of 38.83. Based on the distribution chart, EZZ Life Science Holdings ranks #149 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #149 out of 1199 companies for Return-on-Tangible-Equity. This places EZZ Life Science Holdings in the top 12% of its industry — outperforming the majority of peers. Historically, EZZ Life Science Holdings' own Return-on-Tangible-Equity has ranged from 10.86 to 38.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on EZZ Life Science Holdings and its competitors. EZZ Life Science Holdings's current Return-on-Tangible-Equity is -4.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.45, compared to a current price of A$0.48 — trading 66.9% below its estimated fair value. The current Return-on-Tangible-Equity is -4.59%. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current Return-on-Tangible-Equity is -4.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.48 is trading 66.9% below its estimated GF Value™ of A$1.45.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
Return-on-Tangible-Equity: -4.59%
GF Value™: A$1.45 vs. price of A$0.48 (66.9% below fair value)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score
Get the complete analysis for ASX:EZZ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
